Provided herein are methods and compositions for providing identification and/or traceability of biological materials. In certain embodiments, methods are provided including steps of: determining a sequence of at least one unique identifier sequence in the genomic DNA of a biological entity; validating identification of the biological entity by verifying presence of the unique identifier sequence in the genomic DNA and comparing the sequence of the unique identifier sequence with a database to confirm uniqueness; providing an indication of acceptability to produce a biological material from the biological entity; and inputting the unique identifier sequence into a database entry of the database and associating the unique identifier sequence with identification and/or tracking information; thereby providing traceability by reading the unique identifier sequence and retrieving the corresponding database entry to obtain the identification and/or tracking information. Oligonucleotides, cassettes, and compositions for providing identification and/or traceability of biological materials are also provided.

The disclosure relates to biomarkers for predicting a therapeutic response of a patient to an immune therapy. Since gene signatures and markers according to an aspect have an excellent predictive capacity for predicting a patient's therapeutic response to an immune therapy, a patient group predicted to exhibit therapeutic effects may be selected to perform an appropriate treatment, and a patient's suffering and costs may be reduced.

This invention provides gene expression profiles useful for diagnosing atrial fibrillation in ischemic stroke and for distinguishing atrial fibrillation in ischemic stroke from arterial (large vessel) stroke or embolic stroke of undetermined source (ESUS). In another aspect, the present invention is the provision of an improved method for prognosis of an outcome or assessing the risk of a patient having suffered a stroke or a transient ischemic attack, comprising determining the level of expression of at least one biomarker in a sample of the patient.

An identification system of circulating biomarkers for cancer detection, a development method of circulating biomarkers for cancer detection, a cancer detection method and a kit are provided in the present disclosure, and the development method includes the following steps. Expression levels of multiple genes in normal tissue samples and tumor tissue samples are identified, and genes with high expression levels in the tumor tissue samples are selected. Afterwards, a weight of each human tissue’s contribution to plasma exosomes is calculated using tissue-specific genes and group-enriched genes. Next, expression levels of plasma exosome genes of healthy people and cancer patients are compared by an overlapping index, and circulating biomarkers and combinations thereof suitable for detection and evaluation of plasma exosomes are selected.

Disclosed herein include methods and compositions for culture medias for in vitro culture of synthetic embryos from mammalian pluripotent stem cells and extra-embryonic stem cells. The methods and compositions described herein can generate synthetic embryos at different developmental stage reaching early organogenesis and beyond. Disclosed herein also include an embryo culturing system and methods of using same.

The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for disease in a subject.

The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of lung cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, a method for use of said nucleic acid sequences, which have been isolated, as a molecular marker or molecular markers, and a kit including at least one binding partner specific for at least one of the expression products of the HERV nucleic acid sequences.

The present invention provides compositions and methods for treating cancer with peptide nucleic acid agents. In some embodiments, the present invention provides methods and compositions relating to peptide nucleic acid agents that target oncogenes. For example, the present invention provides compositions, including pharmaceutical compositions, comprising agents specific for BRAF V600E inhibition, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using BRAF V600E specific peptide nucleic acid agents and/or compositions.

An object of the present invention is to provide a kit or a device for the detection of prostate cancer and a method for detecting prostate cancer. The present invention provides a kit or a device for the detection of prostate cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting prostate cancer, comprising measuring the miRNA in vitro.

It is intended to provide a kit or a device for the detection of lung cancer and a method for detecting lung cancer. The present invention provides a kit or a device for the detection of lung cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting lung cancer, comprising measuring the miRNA in vitro.